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rectile Dysfunction in Heart Failure Patients
rnst R. Schwarz, MD, PHD, FACC, FESC,*† Saurabh Rastogi, MD,† Vishal Kapur, MD,†
asir Sulemanjee, MD,† Jennifer J. Rodriguez, MD†
os Angeles, California; and Galveston, Texas
Chronic heart failure (HF) and erectile dysfunction (ED) are 2 highly prevalent disorders that
frequently occur concomitantly. Coronary artery disease, HF, and ED share several common
risk factors, including diabetes mellitus, hypertension, smoking, and dyslipidemia. Addition-
ally, the distinct physiologic sequelae of HF create unique organic and psychologic factors
contributing to ED in this patient population. Standard HF therapy with beta-receptor
blockers, digoxin and thiazide diuretics may worsen sexual dysfunction owing to medication
side effects. This may, in turn, lead to noncompliance in misguided efforts to retain
satisfactory sexual activity, with secondary worsening of cardiac capacity. This review
describes the unique aspects of ED in the HF population. (J Am Coll Cardiol 2006;48:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.0521111–9) © 2006 by the American College of Cardiology Foundation
s
E
h
P
m
i
t
T
o
P
E
N
n
a
p
t
t
n
m
w
d
k
t
a
g
G
p
N
c
w
m
m
prectile dysfunction (ED) is the inability to achieve and/or
aintain a penile erection sufficient enough to participate in
atisfactory sexual activity (1). The 1998 FDA approval of
ildenafil citrate (Viagra) as oral therapy for ED brought
his once “private” disease into the public eye, with increas-
ng interest by patients and physicians alike. Although
uantifying the incidence of ED is inherently difficult, the
assachusetts Male Aging study demonstrated that among
en 40 to 70 years of age, 52% experience some degree of
D (2). As the links between ED and cardiac disease are
nveiled, clinicians are increasingly recognizing ED as an
mportant harbinger of cardiac disease.
Heart failure (HF), also a highly prevalent condition,
hares several risk factors with ED and frequently occurs
oncomitantly. Heart failure patients experience a decreased
ibido and frequency of coitus, negative changes in sexual
erformance, and a general dissatisfaction related to their
exual function (3). Although the coexistence of ED and
oronary atherosclerotic disease (CAD) is well described,
revalence in the HF population is less delineated. In one
mall cohort of 62 HF clinic patients, approximately three-
uarters reported compromised libido and ED (3). In a
ohort of more than 300 HF patients, more than 90%
eported reduced libido and erectile problems, which was
ndependent of the New York Heart Association (NYHA)
unctional class (our data, unpublished). In our own chronic
F population, at least 75% of patients admitted to expe-
iencing ED, regardless of the etiology of their HF (i.e.,
hether ischemic or nonischemic in origin). This suggests
hat HF itself, rather than simply atherosclerosis, contrib-
tes to the development of sexual dysfunction.
From the *Division of Cardiology, Department of Medicine, Cedars-Sinai Medical
enter, Los Angeles, California, and the University of California, Los Angeles, Los
ngeles, California; and the †Division of Cardiology, Department of Internal
edicine, University of Texas Medical Branch, Galveston, Texas.d
Manuscript received March 21, 2006; revised manuscript received April 26, 2006,
ccepted May 1, 2006.Because atherosclerosis is a leading cause of HF, many
hared characteristics of these diseases have been linked to
D. Additionally, physiologic alterations specific to HF
ave been identified as important contributors to ED.
hysicians are increasingly faced with the challenge of
anaging CAD, HF, and ED simultaneously. As such, it is
mperative that we understand the common mechanisms of
hese disease processes and implications of their treatments.
he causes of ED in this population, as well as treatment
ptions, will be discussed in detail.
ATHOPHYSIOLOGY OF
RECTILE FUNCTION AND DYSFUNCTION
ormal sexual function occurs via a symphony of simulta-
eous interplay between psychologic, hormonal, vascular,
nd neurologic factors. Ultimately, erection is a vascular
henomenon, beginning with increased arterial flow into
he corpora cavernosa and spongiosum. Engorgement of
hese chambers eventually compresses venous outflow chan-
els, thereby enlarging and hardening the penis (1). Maxi-
al penile engorgement requires smooth muscle relaxation
ithin the vascular chambers (4). Nitric oxide (NO), pro-
uced by cavernosal nerves and vascular endothelium, is a
ey contributor to the decreased penile vascular tone essen-
ial to normal erectile function (4,5). Nitric oxide stimulates
denylate cyclase, which increases intracellular cyclic
uanosine monophosphate (cGMP) production (4). Cyclic
MP and cyclic adenosine monophosphate (cAMP) are the
rincipal mediators of erectile smooth muscle relaxation (6).
eurogenic NO results in acute vasodilation of the corpus
avernosum, and is therefore crucial to achieving erection,
hereas endothelially released NO plays a greater role in
aintaining an erection (7). Cyclic GMP metabolism,
ediated primarily by intracavernosal type 5 cGMP phos-
hodiesterase, revokes these vasodilatory effects, resulting in
etumescence (8).
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Heart Failure and ED September 19, 2006:1111–9Alterations in any of the systems described can hinder the
bility to achieve and maintain an erection. Inadequate
ascular smooth muscle relaxation is the common final
athway leading to ED, and can be impaired by a number of
rganic and psychogenic conditions that alter the NO-
GMP pathway (7,9). Psychogenic factors such as stress, in
ddition to the treatment of certain psychologic conditions,
ay interfere with erectile function (10). Architectural
bnormalities such as a structural imbalance of trabecular
mooth muscle and connective tissue may hinder penile
ngorgement (11). An imbalance of vascular contractile
norepinephrine, endothelin, and prostanoids) and relax-
tion (vasointestinal polypeptide and NO) mediators can
lso disturb normal erectile function (12).
RECTILE DYSFUNCTION AS
MARKER OF CARDIAC DISEASE
therosclerosis is a systemic vascular disease and is the most
ommon cause of vasculogenic ED in older men (13,14).
rectile dysfunction shares several modifiable risk factors
ith cardiovascular disease, including atherosclerosis (15),
ypertension, hyperlipidemia, diabetes mellitus (16), smok-
ng (17), obesity, and sedentary lifestyle (18). Recent data
uggest that ED may be an indicator of underlying CAD,
nd vice versa.
Men with ED appear to be at higher risk of myocardial
nfarction and peripheral vascular disease (19,20). Among
atients with coronary artery disease, prevalence reports of
D have ranged from 42% to 75% (21–28). Montorsi et al.
eported the rate of ED in patients with CAD to be as high
s 42% to 57%. Conversely, the incidence of positive
xercise stress testing in patients with ED ranged from 5%
o 56% (14). Erectile function has also been correlated with
oronary plaque burden and number of diseased coronary
rteries (21,29).
The overlap between ED and CAD has developed some
nthusiasm for considering ED as penile angina, as well as
stimulus to initiate cardiac screening. Shamloul et al. (30)
eported penile peak systolic velocities less than 35 cm/s to
ave 100% specificity for predicting ischemic heart disease.
n patients with angiographically proven CAD and clinical
D, a study reported that 67% experienced symptoms of
D before coronary symptoms, with sexual symptoms
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ARB  angiotensin-receptor blocker
CAD  coronary atherosclerotic disease
cGMP  cyclic guanosine monophosphate
ED  erectile dysfunction
HF  heart failure
NO  nitric oxide
NYHA  New York Heart Association
PDE-5  phosphodiesterase-5ccurring a mean of 38.8 months earlier. This incidence oncreased to 100% in type I diabetes patients (22). More
ecently, analysis of generally healthy and active men com-
rising the placebo arm of the Prostate Cancer Prevention
rial found that the development of ED frequently pre-
eded development of coronary events, with an adjusted
azard ratio of 1.25 (confidence interval 1.02 to 1.53; p 
.04) for developing angina. Although atherosclerosis is a
ommon cause of HF, the development of ED did not
onfer similar predictive values for developing HF (31).
Endothelial dysfunction appears be a common link be-
ween ED and CAD. Because endothelial dysfunction is a
allmark of chronic HF, the overlap between ED and HF is
ot surprising. Whether endothelial dysfunction plays a role
n ED in nonischemic cardiomyopathy without atheroscle-
osis, however, is unknown. Alterations in the endothelial
-arginine–NO–mediated smooth muscle relaxation path-
ay have been demonstrated in atherosclerotic coronary
rteries of humans and animals (32–35). These findings are
imilar to those seen in the penile L-arginine–NO pathway
nd would support the concept that vasculogenic changes in
he penile vascular bed mirror those in the coronary arteries.
n fact, systemic endothelial-dependent vasodilation is de-
reased in men with ED (36,37). Because ED is associated
ith a high incidence of occult cardiovascular disease (28),
his might be even more pronounced in diabetic patients
ith coronary artery disease but without any cardiovascular
ymptoms.
ACTORS IN HEART FAILURE
ONTRIBUTING TO ERECTILE DYSFUNCTION
eart failure patients may experience ED for a variety of
easons, similarly to the general population. These include
nderlying atherosclerosis, traumatic injury, neurologic pa-
hology, hormonal deficiencies, medication side effects, and
sychogenic contributions. Additionally, HF is a disease
tate with unique social, psychologic, physiologic, and
rug-related consequences that may contribute to the high
ncidence of ED. The various causes and potential mecha-
isms of ED in this patient population have been summa-
ized in Table 1.
sychologic influences. Depression and anxiety are com-
on comorbid conditions in HF. In fact, cardiovascular
isease, ED, and depression have been described as a
utually reinforcing triad (38). It is unknown whether HF
nd/or ED causes depression or if these conditions develop
ndependently. Depressive symptoms may fluctuate with the
atural course of HF and may be due to the physical
imitations affecting daily activities as well as the poor
rognosis of many of these patients (39–41). Performance
nxiety and fear of death also play a role in sexual dysfunc-
ion (42). Further complicating matters, depression, and
nxiety are frequently treated with selective serotonin-
euptake inhibitors (SSRIs), which are well known to
dversely affect sexual function. Additionally, the condition
f ED may play a role in the genesis of depression and
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September 19, 2006:1111–9 Heart Failure and EDnxiety, and successful ED treatment may also improve
hese psychologic conditions.
ardiovascular exercise tolerance. Although difficult to
tandardize, the “average” coitus appears to expend approx-
mately 5 metabolic equivalents or is roughly comparable to
brisk walk up to two flights of stairs (43). Level of sexual
unction appears to have a significant link with the 6-min
alk test. Conversely, there is only a weak correlation with
YHA functional class and no relationship between sexual
erformance and ejection fraction (3). On the other hand,
atients in NYHA class IV may be unlikely to express sexual
esire owing to overwhelming symptoms of dyspnea. In
F, exercise capacity is limited by the inability to increase
eart rate and stroke volume beyond a submaximal stage of
xercise (44). Patients with chronic HF maintain increased
asoconstriction with decreased exercise-induced vasodila-
ion (45). Neurohormonal activation leads to lack of preload
esponse, impaired autonomic regulation, and increased
ascular resistance, all of which appear to contribute to the
lunted hemodynamic response to exercise seen in HF.
dditionally, severely reduced left ventricular function re-
uces cardiac capacity, which may further limit physical
xertion, including that required for satisfactory sexual
ntercourse.
therosclerosis. Atherosclerosis is a systemic disease, and
s the most common cause of cardiomyopathy in the U.S. It
lso accounts for approximately 40% of ED in men over 50
ears of age (15). Intimal hyperplasia and plaque deposition
an create focal stenosis of the common iliac, hypogastric, or
udendal arteries, thereby decreasing arterial inflow into the
able 1. Causes of Erectile Dysfunction in Patients With
eart Failure
Cause Mechanism
sychogenic
● Depression
● Performance Anxiety
● Treatment
● Fear
● Decreased libido
● Increased sympathetic tone
● Medications (i.e., SSRIs)
therosclerosis ● Decreased penile arterial inflow
● Endothelial dysfunction
mpaired cardiovascular
exercise tolerance
● Blunted heart rate response
● Blunted stroke volume
mpaired vasomotion ● Impaired endothelial-independent
vasodilation
● Endothelial dysfunction
● Increased endothelin 1
● Increased noradrenalin
● Decreased prostacyclin
edications
● Beta-adrenergic receptor
blockers (some)
● Digoxin
● Spironolactone
● Diuretics
● Unknown mechanism
● Corporal smooth muscle sodium-pump
inhibition
● Androgen suppression
● Unknown mechanism
SRIs  selective serotonin reuptake inhibitors.enile corpora cavernosa (46). Additionally, atherosclerosis ts associated with endothelial dysfunction, which has also
een implicated in ED (as discussed in detail subsequently).
ltered vasomotion. Endothelial dysfunction has emerged
s a common link between coronary atherosclerosis and ED.
tudies evaluating whether or not NO production is altered
n HF are conflicting (46–52). It has been postulated that
ndothelial damage leads to decreased bioavailability of
ndothelium-derived NO, possibly via mRNA down-
egulation of endothelial NO synthase and cyclooxygenase.
uch a deficiency appears to be specific to the physiologic
tate of HF (53). Other theories link decreased NO bio-
vailability to underlying atherosclerosis, including alter-
tions in the L-arginine–NO pathway (32–35), conse-
uences of oxygen-derived free radicals (54), and cell surface
eceptor abnormalities at the G protein level (55).
Heart failure is also associated with an imbalance of
everal other circulating vasomodulators that work at the
ndothelial level. Increased levels of potent vasoconstrictors,
uch as endothelin, have been demonstrated in HF (56,57).
ndothelin 1 is thought to play a major role in maintaining
mooth muscle tone of the corpus cavernosa by inducing
ustained contractions in the corpus cavernosa and penile
essels (4,58). Endothelin may also modulate other contrac-
ile agents such as noradrenalin (59–61), cellular prolifera-
ion, and/or phenotypic expression (62). These changes are
ccompanied by a reduction in circulating vasodilators such
s prostacyclin (63). This imbalance of vasomodulators
avors vasoconstriction, thereby prohibiting the vascular
vents necessary to achieve and maintain adequate erection.
Heart failure patients also develop dysfunctional
ndothelium-independent vasodilatation (52,64). This may
esult from decreased arterial compliance, impaired respon-
iveness due to cGMP dysfunction, or altered NO diffusion
hrough the arterial wall (65–67). Coupled with endothelial
ysfunction, the effects of these changes may be amplified
linically.
RUG THERAPY IN HEART
AILURE AND ERECTILE DYSFUNCTION
everal of the medications used as cornerstone HF therapy
ave been implicated in causing or worsening ED. In
eneral, most of the studies are small and limited by the
nability to excise medication effects from the consequences
f underlying diseases such as HF, hypertension, and
therosclerosis. Treating HF may attenuate some of these
dverse physiologic adaptations, and it is expected that
mproving cardiac function would improve cardiac capacity.
owever, there are no data establishing whether or not
ffective HF treatment has beneficial, deleterious, or any net
ffect on sexual function.
igoxin. In an analysis of multiple cardiovascular medica-
ions, digoxin has had the highest association with complete
D (68), although the mechanism is not understood. Early
tudies described high serum estrogen, as well as lower
estosterone and luteinizing hormone with digoxin use
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Heart Failure and ED September 19, 2006:1111–969,70). More recent studies did not confirm these results
71–73). Other studies point to digoxin-associated corpo-
eal smooth muscle sodium-pump inhibition, which leads to
orporeal contraction and impaired NO-induced relaxation
68,74).
iuretics. Several diuretics have been associated with sex-
al dysfunction, although the mechanism again remains ill
efined (75). Specifically, the thiazides chlorthalidone and
ydrochlorothiazide have been associated with impaired
exual function (76,77). In one study, 10% to 20% of
atients taking thiazide diuretics experienced decreased
exual function (78). In another study, total sexual symptom
istress score worsened when hydrochlorothiazide was
dded to propranolol therapy. Conversely, patients taking
aptopril did not experience a change in sexual symptoms
ith the addition of hydrochlorothiazide (79). Spironolac-
one, the aldosterone antagonist currently used as standard
F therapy, has antiandrogen effects and thereby may cause
rectile failure, gynecomastia, and decreased libido (1).
hether or not these effects will be seen with the newer
ore selective mineralocorticoid receptor eplerenone re-
ains to be seen (80).
eta-adrenergic receptor blockers. Historically, beta-
lockers have been linked to depressed erectile function
75). Initial theories blamed decreased perfusion pressure
nd/or direct effects on smooth muscle, although the same
dverse sexual effects are not seen with alpha-adrenergic
eceptor blockers. In fact, alpha-blockers may actually im-
rove sexual dysfunction (81). Beta-blockers may also po-
entiate alpha-1 adrenoreceptor–mediated corporal smooth
uscle contraction, thereby interfering with erectile func-
ion (1). Propranolol use appears to be associated with
ignificant sexual dysfunction (79). More recently, carve-
ilol, the now preferred agent for beta-blocker therapy in
F patients, has also been implicated in sexual dysfunction.
recent study comparing carvedilol with the angiotensin-
eceptor blocker (ARB) valsartan demonstrated a decline in
exual activity within the carvedilol-treated group. How-
ver, this was in a hypertensive (not HF) population, and
atients with comorbidities such as diabetes mellitus and
oronary atherosclerosis were excluded. Additionally, it is
nknown if these data represent deleterious effects of
arvedilol or beneficial effects of valsartan (82).
Curiously, sexual side effects are not experienced by the
ajority of patients taking beta-blockers. Studies with both
etoprolol and atenolol have demonstrated neutral effects
n sexual function (76,83). In a study of 96 cardiovascular
atients, 31% reported ED after beginning atenolol and
eing informed of its possible adverse sexual side effects.
owever, only 3% of men who were similarly treated
eported ED when they were blinded to the study drug,
uggesting that ED with beta-blockers is related to patient
nowledge of these potential side effects (84). The disparate
esults of these varied beta-blockers and dosages may be
elated, at least in part, to separate actions on peripheral
tructures and the central nervous system (85). iIn our own experience, however, several HF patients who
xperienced reduced libido, ED, and even depression while
eing treated with metoprolol (as, in the past, with atenolol)
howed improved erections after being switched to carve-
ilol. This may be due to improved contractile function in
ddition to the alpha-blocking properties and the resultant
mproved perfusion.
ngiotensin-converting enzyme inhibitors and angiotensin-
eceptor blockers. The impact of angiotensin-converting
nzyme (ACE) inhibitors and ARBs on ED is equally
lusive. Angiotensin-converting enzyme inhibitors, particu-
arly captopril, have been associated with improved sexual
unction (86,87). Although some supporters attribute these
enefits to improved cardiac function, there are insufficient
ata to support this. There is an even greater paucity of data
egarding the effects of the newer ARBs on sexual function.
Japanese study reported that hypertensive patients 65
ears of age experienced improved sexual function when
witched from a calcium-channel blocker to candesartan
88). When the ARB valsartan was compared with the
eta-blocker carvedilol, long-term therapy with valsartan
as associated with improved sexual activity (82). Dusing
89) confirmed these results when he reported improved
rgasmic function, intercourse, and overall sexual satisfac-
ion in hypertensive patients treated for 6 months with
alsartan. Once again, data specific to the HF population
re lacking. In our own patients, we have frequently replaced
CE inhibitors with ARBs and have achieved mixed
esults.
REATING ERECTILE DYSFUNCTION
N THE HEART FAILURE PATIENT
afe sex in heart failure. In general, the metabolic de-
ands of sexual activity are modest. The safety of engaging
n sex, similarly to other physical activities, depends on the
ardiovascular reserve of the patient. The Second Princeton
onsensus Conference offers guidelines to assessing the risk
f sexual activity in all cardiac patients, including the HF
atient. Patients whose symptoms are NYHA class I are not
onsidered to be at increased risk of coitus-induced cardio-
ascular events. Those patients with NYHA class II symp-
oms are classified as “intermediate/indeterminate” risk of
xacerbating symptoms during sexual activity and should be
roperly assessed and rehabilitated so that they can be
estratified into the “low- or high-risk” category before
exual activity. Although the exact risk is not known, HF
atients with NYHA class III or IV symptoms are consid-
red to be at “high-risk” for further decompensation with
exual activity. Under these guidelines, high-risk patients
hould be treated and stabilized before engaging in coitus
90). Even more in diabetic patients with HF and CAD, it
s recommended not only to stabilize the cardiac condition
ut also to exclude silent myocardial ischemia before resum-
ng sexual activity or starting treatment for ED.
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September 19, 2006:1111–9 Heart Failure and EDImportantly, the aforementioned guidelines are based
n current knowledge of pathophysiologic demands of
exual activity and physiologic alterations of HF but not
n randomized controlled trials. In our own experience
ith patients with stable NYHA class III symptoms, we
ave recommended ED therapy, if warranted, and have seen
atisfactory results, whether patients were treated with
hosphodiesterase-5 (PDE-5) inhibitors or even with im-
lantable devices (as described subsequently).
anaging heart failure. Intuitively, the first goal for
reating patients with HF and ED is to optimize HF
herapy, as endorsed by the newly updated American
ollege of Cardiology/American Heart Association guide-
ines (91). Improved cardiac status may reduce symptoms,
mprove exercise capacity, and decrease depression, thereby
econdarily improving sexual activity. Several studies have
emonstrated improved endothelial function in HF patients
eceiving various medical therapies, including ACE inhib-
tors, ARBs, statins, and dobutamine therapy (92–96). This
ay be due to the medications themselves and/or physio-
ogic shifts from cardiac compensation. One would expect
hat improvement in such endothelial function would im-
rove erectile function.
Next, cardiologists should inquire about sexual function
nd its role in the individual patient’s life, because this is
nfortunately not standard care in the primary care (or most
ardiologists’) practice. If clinically feasible, drugs with
otential adverse sexual side effects should be discontinued
r replaced. The practices we have included in our own
ultidisciplinary sexual health clinic (for high-risk cardiac
atients) include avoiding digoxin and thiazide diuretics as
ell as replacing beta-blockers such as propranolol with
arvedilol (owing to its additional alpha-blocking effects).
dditionally, we would recommend replacing spironolac-
one with eplerenone, because one would expect the more
elective agent to have less antiandrogen effects. After the
receding adjustments have been made, we would then
ecommend a more specific approach to ED.
hosphodiesterase-5 inhibitors in heart failure. Silde-
afil citrate (Viagra) was the first oral drug approved for ED
n the U.S. The newer PDE-5 inhibitors vardenafil (Lev-
tra) and tadalafil (Cialis) appear to be as effective as
ildenafil (65–69). By inhibiting type 5 phosphodiesterase,
he PDE-5 inhibitors enhance cGMP-NO–mediated vaso-
ilatation by preventing PDE-5 catabolism of cGMP and
hereby delaying detumescence. The PDE-5 inhibitors
ncrease the number and duration of erections as well as the
ercentage of successful sexual intercourse (97,98).
The American College of Cardiology and the American
eart Association expressed concerns in their 1999 consen-
us document regarding the lack of cardiovascular safety
ata from controlled clinical trials of sildenafil in men who
ad ED and congestive HF. Initially, HF was listed as a
elative contraindication for the use of sildenafil, owing to
oncerns of concomitant use of other vasodilators that could
esult in significant hypotension, but perhaps more owing do lack of data in the HF population (99). Subsequently,
multicenter, prospective, randomized, double-blind, placebo-
ontrolled, flexible-dose trial demonstrated that flexible dos-
ng of sildenafil from 25 to 100 mg was well tolerated,
mproved erectile function, and increased sexual satisfaction
n ambulatory subjects with mild to moderate (congestive)
F (100). These findings echoed the results of 2 earlier
maller investigations (101,102).
Also of interest are potential hemodynamic benefits of
ildenafil in the HF patient. Despite initial concerns that
ildenafil-induced vasodilation may provoke a reflex tachy-
ardia, this has not been substantiated in clinical trials.
occhi et al. (101) studied several hemodynamic parameters
n HF patients treated with sildenafil during the 6-min walk
est and maximal exercise testing. Sildenafil decreased heart
ate response throughout the 6-min walk test and increased
he total exercise time. Basal blood pressure was slightly
ower before either test, but there was no difference during
xercise. In their study of sildenafil use in HF patients,
ebster et al. (102) found no significant change in blood
ressure or heart rate from baseline. More recently, a small
tudy by Hirata et al. (103) further confirmed that sildenafil
se decreased heart rate acutely. Additionally, they reported
significant increase in cardiac index (by 0.37 l/min  m2),
hich is likely due to the observed reduction in total
ystemic resistance. Another potential hemodynamic benefit
f sildenafil in HF is that at low doses, it has been shown to
ncrease endothelium-dependent flow-mediated vasodila-
ion (104).
There are, however, some remaining concerns that have
een raised regarding the long-term effects of sildenafil use
n HF. Chronic use of milrinone, a PDE-3 inhibitor, has
een associated with increased mortality in patients with
oderate to severe CHF (105). There is a theoretical risk
hat long-term use of PDE-5 inhibitors, because they cause
ome degree of PDE-3 inhibition as well, also may prove to
e harmful. However, because sildenafil is highly selective
or PDE-5 inhibition, it would seem unlikely to signifi-
antly alter myocellular cAMP levels as is seen with long-
erm milrinone use. Previous experiments evaluating the
ffects of PDE-5 inhibition on levels of cyclic nucleotides
nd cardiac contractility have been inconsistent, likely ow-
ng to differing species, pharmacologic agents, and doses.
vailable clinical data in patients with ischemic heart
isease, HF, and primary pulmonary hypertension demon-
trate systemic vasodilation without clear chronotropic and
notropic effects (106).
Although the newer PDE inhibitors vardenafil and
adalfil may not pose additional cardiac risks, no clinical
afety data on their use is available in the HF patient
opulation. As of now, we preferably recommend sildenafil,
nd sometimes vardenafil, for safe use in chronic stable HF
atients. In general, tadalafil should be avoided owing to its
onger half-life. We usually start low-dose sildenafil at 25 to
0 mg, with repeated use on separate days, and eventual
ose increments up to 100 mg. All of the PDE-5 inhibitors
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Heart Failure and ED September 19, 2006:1111–9otentiate the hypotensive effects of nitrates and are con-
raindicated with concomitant nitrate or other NO donator
se (nitroprusside, molsidomine) (6).
In general, most HF patients are initially successfully
reated with PDE-5 inhibitors, whereby success in clinical
tudies is measured as improvement of erections or other
arkers, such as the International Index of Erectile Func-
ion score. In follow-up of our own patients, however, only
0% to 40% of patients remain on PDE-5 inhibitors long
erm and might seek further ED treatment (such as surgical
lternatives) in the future.
ther oral therapy. Currently, there are no data support-
ng the efficacy of nutritional supplements, herbal therapy,
r vitamins in the treatment of ED in the general or HF
opulation (107). Other commonly seen oral drugs for the
reatment of ED are apomorphine (Apokyn, Uprima) and
ohimbine (Yocon). Apomorphine is centrally acting and
as shown mild clinical efficacy in treatment of ED (108);
owever, it is currently unavailable in the U.S. Yohimbine is
n alpha-2 receptor blocker with limited efficacy in the
reatment of ED (109). Its use is not recommended in the
F patient owing to its cardiovascular side effects, including
achycardia and hypertension.
ther traditional ED therapy. In the HF population, there
re currently no known adverse cardiovascular effects to andro-
en replacement therapy when indicated, intraurethral sup-
ositories, penile prosthesis, or vacuum-assist erection de-
ices. However, penile injection therapies (and sometimes
acuum device therapy) have some risks in HF patients who
re on chronic anticoagulation. Although no large-scale
ata have reported severe bleeding episodes in patients
aking aspirin and clopidogrel, patients treated with warfa-
in would not be ideal candidates for these therapies owing
o increased bleeding risks. In general, these therapies are
est guided by the expertise of a urologist in close collabo-
ation with the patient’s cardiologist (110).
urgical management of ED. Penile revascularization sur-
ery is another treatment alternative for ED resulting from
iscrete localized arterial lesions. However, only a minority
f ED patients have suitable vascular anatomy, and finding
vascular surgeon experienced in this uncommon procedure
an prove to be difficult. Unfortunately, many urologists are
eluctant to perform such elective surgeries in the HF
atient, and long-term results are not very convincing.
urgical implants of penile prostheses are usually a last
esort for men who have failed all other medical and
emi-invasive treatments (111,112). These may, however,
epresent a viable alternative in otherwise untreatable ED in
he HF population, as long as these patients are in opti-
ized and stable cardiac condition. In our own HF patients,
e are referring increasing number of patients for device
mplantation with good and satisfactory success rates. Even
hough it is an invasive surgical procedure, penile implant
herapy as a last resort of ED treatment has been shown to
ave the highest success and satisfaction rates (113), even in
ur own HF population. pFinally, percutaneous transluminal angioplasty (PTA), is
merging as a potential treatment modality for patients with
ocal atherosclerotic lesions of the hypogastric (internal
liac), common iliac, or pudendal arteries. Few and small
tudies have reported success rates of 57% to 84% with
esolution of ED after PTA of the common and external/
nternal iliac arteries as well as of the internal pudendal
rteries (114–116). Randomized controlled studies are re-
uired to establish the definitive role of PTA in the
reatment of arteriogenic impotence. At this time, it is a
otential future treatment option for a select group of
atients. This may become a suitable alternative for HF
atients, because it would avoid the cardiovascular risks of
eneral anesthesia.
REATING DEPRESSION
sychologic counseling aids symptoms of depression and
ay thereby improve sexual function. However, as men-
ioned, many of the newer and more effective antidepres-
ants, such as the selective serotonin reuptake inhibitors, can
ecrease libido and/or worsen erectile function (117). Con-
ersely, trazodone, clomipramine, and other tricyclic anti-
epressants may cause delayed or retarded ejaculation,
hich would benefit men suffering from premature ejacu-
ation (41,118). A small study demonstrated that HF
atients with ED who were treated with sildenafil had
mprovement in depression scores during the treatment
eriod (102). This finding further emphasizes the impor-
ance of the HF-ED-depression triad. The net effect of
reating depression with potentially sexually deleterious
edications remains unknown. An ethically reasonable
pproach is to adequately treat depression and then to
ounteract medication side effects with the use of PDE-5
nhibitors if necessary.
EXUAL COUNSELING
atients may become noncompliant with their HF medical
egimen, fearing that such medications cause or worsen
exual function. Many cardiac patients are uncomfortable
iscussing sexual function (119), despite their informational
eeds and desire to discuss their sexual health (119,120). To
ispel fear and anxiety, couples should receive information
bout the physiologic requirements of sexual activity, the
athophysiology of HF (including its treatment) relative to
exual function, and the psychologic sequelae of HF. Al-
hough the literature describes HF patients as reluctant to
iscuss sexual function, it has been our own experience that
hen approached by their physician, patients are welcoming
nd appreciative of the opportunity to discuss this topic and
xplore treatment options.
UTURE TREATMENTS
he Rho A/Rho kinase pathway is emerging as a novel
layer in the regulation of penile erection, and future
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September 19, 2006:1111–9 Heart Failure and EDnvestigations may further define its role in ED and HF
121). Neovascularization is another emerging therapy for
he treatment of arteriogenic ED. Intracavernosal injection
f vascular growth factors has been demonstrated in animal
odels and may eventually become another therapeutic
ption (122). Further clinical studies with selective endo-
helin antagonists should be considered, given their estab-
ished elevation in HF and causative role in ED. Gene
herapy may also play a future role; studies are currently
eing conducted in animals with gene transfer of endothelial
O synthase to the penises of aged rats (123).
ONCLUSIONS
rectile dysfunction is highly prevalent among HF patients,
nd can significantly and adversely affect quality of life.
rectile dysfunction, CAD, and HF share risk factors as
ell as underlying disease mechanisms, such as atheroscle-
osis and endothelial dysfunction. Additionally, there are
nique sequelae to HF that may also contribute to ED,
ncluding depression, neurohormonal changes, an imbal-
nce of circulating vasomodulators, reduced cardiac capac-
ty, and potential adverse effects of HF medical therapy.
reatment with sildenafil is a safe option, but safety data on
he newer PDE-5 inhibitors are lacking in the HF popula-
ion. Despite the unique issues of sexual dysfunction in the
etting of HF, most patients are not receiving adequate
ounseling in this matter. By raising physician and patient
wareness of this common and important issue, we create
he opportunity to further impact our patients’ lives in a
eaningful and positive way.
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